New shot aims to control blood cancer without hospital stays
NCT ID NCT07191249
Summary
This study is testing a new under-the-skin injection called mosunetuzumab for people with a slow-growing type of blood cancer called follicular lymphoma who haven't had any treatment yet. The goal is to see if this immunotherapy can effectively shrink tumors while being more convenient, as it doesn't require mandatory hospital stays. About 30 patients will receive the injections for up to 6 months and be followed for 2 years to check how well the cancer responds and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.